Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
22
04
2020
accepted:
09
07
2020
pubmed:
21
8
2020
medline:
15
5
2021
entrez:
21
8
2020
Statut:
ppublish
Résumé
The utility of the Simplified Psoriasis Index (SPI), a recently developed multidomain tool for assessing psoriasis, was investigated in a study assessing response to secukinumab. In an open-label, multicentre study involving 17 French centres, patients with moderate-to-severe plaque psoriasis received secukinumab 300 mg subcutaneously once weekly from baseline to W4, then every 4 weeks until W48. Dermatologist-scored SPI psoriasis severity (proSPI-s) was compared with Psoriasis Area and Severity Index (PASI). Patient self-assessed severity (saSPI-s) and psychosocial impact (SPI-p) were compared with PASI and Dermatology Life Quality Index (DLQI), respectively. We included 120 patients (69.2% male; mean age 45.9 years; mean duration of psoriasis 21.6 years). Mean baseline scores were as follows: proSPI-s 24.9, saSPI-s 23.5, PASI 23.1, SPI-p 8.2 and DLQI 13.6. Severity scores achieved by 16 weeks (proSPI-s 2.3, saSPI-s 2.2 and PASI 2.2) were maintained to W52. Reductions in mean psychosocial impact scores were maintained to W52 (SPI-p and DLQI, respectively, 2.1 and 1.5 at W16; 1.5 and 1.9 at W52). Decrease of PASI scores in response to secukinumab was closely correlated with proSPI-s, supporting the latter's suitability for assessing response to therapy. Although the correlation between PASI and saSPI-s was slightly weaker, patients were able to complete a valid assessment of their psoriasis independently, and thus potentially remotely. With the added benefit of psychosocial impact assessment (SPI-p), SPI provides a valid tool enabling patients to assess their own psoriasis, remotely if necessary.
Sections du résumé
BACKGROUND
BACKGROUND
The utility of the Simplified Psoriasis Index (SPI), a recently developed multidomain tool for assessing psoriasis, was investigated in a study assessing response to secukinumab.
METHODS
METHODS
In an open-label, multicentre study involving 17 French centres, patients with moderate-to-severe plaque psoriasis received secukinumab 300 mg subcutaneously once weekly from baseline to W4, then every 4 weeks until W48. Dermatologist-scored SPI psoriasis severity (proSPI-s) was compared with Psoriasis Area and Severity Index (PASI). Patient self-assessed severity (saSPI-s) and psychosocial impact (SPI-p) were compared with PASI and Dermatology Life Quality Index (DLQI), respectively.
RESULTS
RESULTS
We included 120 patients (69.2% male; mean age 45.9 years; mean duration of psoriasis 21.6 years). Mean baseline scores were as follows: proSPI-s 24.9, saSPI-s 23.5, PASI 23.1, SPI-p 8.2 and DLQI 13.6. Severity scores achieved by 16 weeks (proSPI-s 2.3, saSPI-s 2.2 and PASI 2.2) were maintained to W52. Reductions in mean psychosocial impact scores were maintained to W52 (SPI-p and DLQI, respectively, 2.1 and 1.5 at W16; 1.5 and 1.9 at W52).
CONCLUSIONS
CONCLUSIONS
Decrease of PASI scores in response to secukinumab was closely correlated with proSPI-s, supporting the latter's suitability for assessing response to therapy. Although the correlation between PASI and saSPI-s was slightly weaker, patients were able to complete a valid assessment of their psoriasis independently, and thus potentially remotely. With the added benefit of psychosocial impact assessment (SPI-p), SPI provides a valid tool enabling patients to assess their own psoriasis, remotely if necessary.
Identifiants
pubmed: 32815591
doi: 10.1111/jdv.16893
pmc: PMC7984225
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
677-684Subventions
Organisme : Novartis Pharma France
Informations de copyright
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
J Invest Dermatol. 2014 Feb;134(2):351-358
pubmed: 23897275
Clin Dermatol. 2010 Jan-Feb;28(1):67-72
pubmed: 20082954
J Am Acad Dermatol. 2017 Oct;77(4):667-674
pubmed: 28780364
J Am Acad Dermatol. 2017 Jan;76(1):70-80
pubmed: 27707593
J Invest Dermatol. 2012 Sep;132(9):2171-5
pubmed: 22592157
J Invest Dermatol. 2010 Apr;130(4):933-43
pubmed: 20043014
Int J Dermatol. 2014 Jun;53(6):714-22
pubmed: 23557000
Clin Dermatol. 2008 Sep-Oct;26(5):448-59
pubmed: 18755363
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514
pubmed: 29444376
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9
pubmed: 27663079
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90
pubmed: 25243910
Ann Dermatol Venereol. 2019 Dec;146(12):783-792
pubmed: 31623858
Br J Dermatol. 1991 Jun;124(6):565-70
pubmed: 2064940
Br J Dermatol. 2015 Feb;172(2):484-93
pubmed: 25132411
J Dermatolog Treat. 2007;18(6):351-60
pubmed: 17907013
J Invest Dermatol. 2013 Aug;133(8):1956-62
pubmed: 23807685
J Dermatolog Treat. 2015 Feb;26(1):23-31
pubmed: 24354461
J Am Acad Dermatol. 2015 Sep;73(3):400-9
pubmed: 26092291
Br J Dermatol. 2019 Nov;181(5):954-966
pubmed: 30367462